Individualizing Insulin Therapy in the Management of Type 2 Diabetes

被引:14
|
作者
Moghissi, Etie [1 ]
King, Allen B. [2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[2] CA Diabet Care Ctr, Salinas, CA USA
关键词
Diabetes management; Glycemic target; Individualizing therapy; Insulin; Type; 2; diabetes; TO-TARGET TRIAL; GLYCEMIC CONTROL; PARALLEL-GROUP; NPH INSULIN; OPEN-LABEL; GLUCOSE CONTROL; DETEMIR; MELLITUS; EXENATIDE; ALGORITHM;
D O I
10.1016/j.amjmed.2014.07.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is recognized that reducing hyperglycemia early on in disease progression has long-term benefits for patients with diabetes. Insulin therapy has greater potential to reduce hyperglycemia than other therapies; however, there is often a significant delay in insulin initiation and intensification. Insulin replacement therapy in type 2 diabetes should no longer be viewed as the treatment of last resort. With the development of modern insulin analogs, the field has evolved. Large clinical trials have improved our understanding of the potential benefits and risks associated with intensive glycemic control in different patient populations and highlighted the need for individualization of glycemic targets and treatment strategies. Current treatment guidelines recognize the important role of insulin therapy both early on and throughout the progression of type 2 diabetes. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:S3 / S10
页数:8
相关论文
共 50 条
  • [21] Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
    Home, Philip
    Riddle, Matthew
    Cefalu, William T.
    Bailey, Clifford J.
    Bretzel, Reinhard G.
    del Prato, Stefano
    Leroith, Derek
    Schernthaner, Guntram
    van Gaal, Luc
    Raz, Itamar
    DIABETES CARE, 2014, 37 (06) : 1499 - 1508
  • [22] Why and how to use insulin therapy earlier in the management of type 2 diabetes
    Meneghini, Luigi
    SOUTHERN MEDICAL JOURNAL, 2007, 100 (02) : 164 - 174
  • [23] Differentiated insulin therapy in type 2 diabetes
    Liebl, A.
    DIABETOLOGE, 2008, 4 (07): : 516 - +
  • [24] Insulin Therapy for Type 2 Diabetes Mellitus
    Wallia, Amisha
    Molitch, Mark E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (22): : 2315 - 2325
  • [25] Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting
    Nichols, Gregory A.
    Gandra, Shravanthi R.
    Chiou, Chiun-Fang
    Anthony, Mary S.
    Alexander-Bridges, Maria
    Brown, Jonathan B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) : 9 - 15
  • [26] Forms of insulin therapy of type 2 diabetes
    Liebl, A.
    DIABETOLOGE, 2012, 8 (06): : 501 - 512
  • [27] Insulin analogs for the management of type 2 diabetes
    Taylor, James R.
    Campbell, Kendall M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (04) : 320 - 334
  • [28] Basal-bolus insulin therapy and glycemic control in adult patients with type 2 diabetes mellitus: A review of the literature
    Jackson, Bridget
    Grubbs, Laurie
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2014, 26 (06) : 348 - 352
  • [29] Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin
    Blak, B. T.
    Smith, H. T.
    Hards, M.
    Curtis, B. H.
    Ivanyi, T.
    DIABETIC MEDICINE, 2012, 29 (07) : E13 - E20
  • [30] Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients
    Pan, Chang-Yu
    Sinnassamy, Patrick
    Chung, Kab-Do
    Kim, Kwang-Won
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) : 111 - 118